Valuation: Adimmune Corporation

Market Cap 7.31B 227M 198M 183M 168M 318M 21.83B 324M 2.18B 858M 10.66B 851M 832M 36.81B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 7.93B 246M 215M 198M 182M 345M 23.66B 351M 2.37B 930M 11.55B 922M 902M 39.89B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.19%
Yield 2024 *
-
Yield 2025 -
1 day-0.57%
1 week-1.70%
Current month-1.42%
1 month-0.57%
3 months-7.22%
6 months-15.37%
Current year-8.44%
1 week 16.65
Extreme 16.65
17.55
1 month 16.65
Extreme 16.65
18.2
Current year 16.65
Extreme 16.65
21.5
1 year 16.65
Extreme 16.65
22.5
3 years 15.9
Extreme 15.9
38
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member - 20/06/2019
Director/Board Member - 15/08/2011
Director/Board Member - 29/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%-1.70%+0.87%-50.99% 228M
+2.18%+1.65%+23.91%-5.51% 67.6B
+0.85%-4.92%+40.11%+199.67% 51.32B
+0.94%+39.60%+39.60%+39.60% 42.97B
+0.53%-0.16%-50.61%-52.60% 40.81B
+5.92%+5.03%+62.63%-25.10% 29.12B
-7.51%-17.52%+96.97%-47.96% 27.09B
+1.36%-1.58%+68.50%+88.88% 22.99B
-6.10%-1.34%-0.67%+180.95% 21.55B
+2.15%-2.72%+64.59%+129.01% 16.38B
Average -0.01%-1.24%+34.59%+45.60% 32.01B
Weighted average by Cap. +0.50%-1.19%+32.43%+48.25%

Financials

2024 2025
Net sales 1.56B 48.24M 42.17M 38.99M 35.78M 67.72M 4.65B 68.9M 465M 183M 2.27B 181M 177M 7.84B 1.4B 43.42M 37.95M 35.1M 32.21M 60.96M 4.18B 62.02M 419M 164M 2.04B 163M 159M 7.05B
Net income -243M -7.52M -6.57M -6.08M -5.58M -10.56M -725M -10.74M -72.5M -28.48M -354M -28.24M -27.62M -1.22B -240M -7.43M -6.5M -6.01M -5.51M -10.43M -716M -10.62M -71.65M -28.15M -350M -27.91M -27.3M -1.21B
Net Debt 140M 4.32M 3.78M 3.5M 3.21M 6.07M 417M 6.18M 41.68M 16.37M 203M 16.24M 15.88M 702M 612M 18.97M 16.58M 15.33M 14.07M 26.63M 1.83B 27.09M 183M 71.84M 893M 71.24M 69.67M 3.08B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
16/07/26 NT$17.35 -0.57% 622,174
15/07/26 NT$17.45 +3.56% 1,422,965
14/07/26 NT$16.85 -1.17% 1,554,261
13/07/26 NT$17.05 -3.40% 2,324,953
09/07/26 NT$17.65 0.00% 541,637
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock